Search

Your search keyword '"Liberopoulos, E"' showing total 698 results

Search Constraints

Start Over You searched for: Author "Liberopoulos, E" Remove constraint Author: "Liberopoulos, E"
698 results on '"Liberopoulos, E"'

Search Results

1. Assessing a Pharmacist-Enabled Intervention to Improve Adherence to Medication for Hypertension, Dyslipidemia, and Chronic Venous Circulation Disorders in Greece

2. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023

4. Remnant cholesterol in atherosclerotic cardiovascular disease: a systematic review and meta-analysis

5. Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study

6. Lipids and RAS blockers plus CCB combinations. Alternations in prediabetic hypertensive patients, a randomized 12-week open-label comparative study

7. Metabolic syndrome and atherosclerotic cardiovascular disease in non-diabetic adult patients with familial hypercholesterolemia: Data from the Hellas-FH registry

10. Triglycerides and atherosclerotic cardiovascular disease in adult patients with familial hypercholesterolemia: Data from the Hellas-FH registry

12. Overweight/obesity and prevalent atherosclerotic cardiovascular disease in patients with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry

14. One year follow-up of cardiovascular profile and therapeutic management of children and adolescents with familial hyphercholesterolemia: Preliminary data from the Hellas-FH registry

18. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES

20. Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients

22. One year follow-up of patients with familial hypercholesterolemia: Preliminary data from the HELLAS-FH registry

23. Comparative effect of delapril-manidipine treatment versus valsartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients

24. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: An analysis from the hellas-fh

27. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients

29. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients

31. Laboratory findings and clinical outcomes of 681 COVID-19 patients with dyslipidemia requiring hospitalization

32. Association of TG/HDL-C and TYG indices with the prevalence of atherosclerotic cardiovascular disease in adult patients with familial hypercholesterolemia

33. The possible role of TyG index and TRG/HDL, CRP/HDL, NEUTROPHILS/HDL lymphocytes/HDL ratios in disease severity and outcomes in COVID-19 hospitalized patients with arterial hypertension

34. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients

35. Comparative effect of delapril-manidipine treatment versus valsartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients

37. Thrombotic and thromboembolic events in COVID-19 patients: Association with clinical presentation, progression and laboratory findings. Data analysis of a 681 patient cohort

38. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients

41. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with valsartan/amlodipine in prediabetic hypertensive patients

42. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with telmisartan/amlodipine in prediabetic patients

43. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with valsartan/amlodipine in prediabetic patients

44. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with telmisartan/amlodipine in prediabetic hypertensive patients

45. Changes in TRG/ApoA-1 ratio, TRG/HDL-C ratio and lipid serum profile after combination therapy with manidipine/delapril in prediabetic hypertensive patients

46. Alternations in markers of insulin resistance: HOMA-IR, HOMA-B, QUICKI, after dual therapy combination with delapril/manidipine in prediabetic hypertensive patients

47. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

48. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Catalog

Books, media, physical & digital resources